Recombinant Human NRG1/HRG1 Protein, CF

Catalog # Availability Size / Price Qty
5898-NR-050
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (18)
FAQs
Supplemental Products
Reviews

Recombinant Human NRG1/HRG1 Protein, CF Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a serum-free cell proliferation assay using MCF‑7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED50 for this effect is 20‑100 ng/mL.
Source
Mouse myeloma cell line, NS0-derived human Neuregulin-1/NRG1 protein
Ser20-Lys241, with a C-terminal 6-His tag
Accession #
N-terminal Sequence
Analysis
Ser20
Predicted Molecular Mass
24.8 kDa
SDS-PAGE
40-43 kDa, reducing conditions

Complete Your Experiment

Product Datasheets

You must select a language.

x

5898-NR

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

5898-NR

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Neuregulin-1/NRG1

Neuregulin-1 (NRG1) belongs to a family of structurally related glycoproteins encoded by four distinct but related genes, Nrg1, Nrg2, Nrg3, and Nrg4. Through alternative splicing or the use of alternative promoters, Nrg1 encodes more than 14 soluble or transmembrane proteins. Type I NRG1 isoforms include Neu Differentiation Factor, Heregulin, and ARIA. These consist of an N-terminal domain, an Ig-like domain, a linker with a Ser/Thr rich region, an EGF-like domain, a transmembrane segment, and a cytoplasmic domain. Type II isoforms such as Glial Growth Factor have a larger N-terminal domain and lack the Ser/Thr rich linker. Type III isoforms such as Sensory and Motor neuron-Derived Factor lack the Ig-like domain but contain a cysteine rich domain (CRD) and a second transmembrane segment (1 - 5). The alpha and beta splice variants of NRG1 differ in their extracellular juxtamembrane regions (3, 6). This recombinant protein corresponds to the extracellular domain (ECD) of the type I alpha isoforms (Accession # Q7RTV8). NRG1 isoforms exhibit distinct expression patterns and functions (7). The EGF-like domain, which is common to all NRG1 isoforms, is required for Neuregulin binding to ErbB3 or ErbB4 receptors (3). ErbB3 or ErbB4 subsequently heterodimerize with ErbB2, resulting in tyrosine phosphorylation and NRG1 induced signaling (1, 2). Soluble growth factors can be released by TACE/ADAM17, BACE, or ADAM19 mediated shedding of the ECD of transmembrane NRG1 (8 - 10). The cytoplasmic region can be cleaved by gamma -secretase, generating a repressor that inhibits the transcription of proapoptotic genes (11). NRG1 regulates multiple nervous system functions including axon guidance, synapse formation and plasticity, glial cell development, and axon myelination (1, 2). In the heart, NRG1 regulates organ morphogenesis and contractility and also plays a cardioprotective role following tissue injury (12). Multiple polymorphisms and aberrant expression of NRG1 isoforms are associated with the development of schizophrenia and many cancers (1, 2, 13).

References
  1. Mei, L. and W.-C. Xiong (2008) Nat. Rev. Neurosci. 9:437.
  2. Talmage, D.A. (2008) Novartis Found. Symp. 289:74.
  3. Holmes, W.E. et al. (1992) Science 256:1205.
  4. Marchionni, M.A. et al. (1993) Nature 362:312.
  5. Ho, W.-H. et al. (1995) J. Biol. Chem. 270:14523.
  6. Wen, D. et al. (1994) Mol. Cell. Biol. 14:1909.
  7. Meyer, D. et al. (1997) Development 124:3575.
  8. Hu, X. et al. (2006) Nat. Neurosci. 9:1520.
  9. Willem, M. et al. (2006) Science 314:664.
  10. Yokozeki, T. et al. (2007) Genes Cells 12:329.
  11. Bao, J. et al. (2003) J. Cell Biol. 161:1133.
  12. Lemmens, K. et al. (2007) Circulation 116:954.
  13. Breleux, M. (2007) Cell. Mol. Life Sci. 64:2358.
Entrez Gene IDs
3084 (Human); 211323 (Mouse); 112400 (Rat)
Alternate Names
ARIA; GGF2; GGFglial growth factor; Heregulin-1; HGL; HGLneu differentiation factor; HRG; HRG1; HRG1-alpha; HRG1-beta 1; HRGAneuregulin 1 type IV beta 1a; MST131; MSTP131; NDFheregulin, alpha (45kD, ERBB2 p185-activator); neuregulin 1 type IV beta 3; neuregulin 1; Neuregulin1; Neuregulin-1; NRG1; pro-neuregulin-1, membrane-bound isoform; pro-NRG1; sensory and motor neuron derived factor; SMDF

Citations for Recombinant Human NRG1/HRG1 Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

18 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Cordycepin inhibits the proliferation of malignant peripheral nerve sheath tumor cells through the p53/Sp1/tubulin pathway
    Authors: MJ Lee, JC Lee, JH Hsieh, MY Lin, IA Shih, HL You, K Wang
    American journal of cancer research, 2021;11(4):1247-1266.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting
    Authors: Z Du, BP Brown, S Kim, D Ferguson, DC Pavlick, G Jayakumara, R Benayed, JN Gallant, YK Zhang, Y Yan, M Red-Brewer, SM Ali, AB Schrock, A Zehir, M Ladanyi, AW Smith, J Meiler, CM Lovly
    Nature Communications, 2021;12(1):1382.
    Species: Primate - Cercopithecus Aethiops
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Mapping Development of the Human Intestinal Niche at Single-Cell Resolution
    Authors: EM Holloway, M Czerwinski, YH Tsai, JH Wu, A Wu, CJ Childs, KD Walton, CW Sweet, Q Yu, I Glass, B Treutlein, JG Camp, JR Spence
    Cell Stem Cell, 2020;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice
    Authors: JS Lee, JY Lee, DW Song, HS Bae, HM Doo, HS Yu, KJ Lee, HK Kim, H Hwang, G Kwak, D Kim, S Kim, YB Hong, JM Lee, BO Choi
    Nucleic Acids Res., 2019;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Cell Culture
  5. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
    Authors: TA Ahmed, C Adamopoulo, Z Karoulia, X Wu, R Sachidanan, SA Aaronson, PI Poulikakos
    Cell Rep, 2019;26(1):65-78.e5.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
    Authors: T Osada, ZC Hartman, J Wei, G Lei, AC Hobeika, WR Gwin, MA Diniz, N Spector, TM Clay, W Chen, MA Morse, HK Lyerly
    Breast Cancer Res., 2018;20(1):90.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response
    Authors: JP Turowec, EWT Lau, X Wang, KR Brown, FA Fellouse, KK Jawanda, J Pan, J Moffat, S Sidhu
    J. Biol. Chem., 2018;0(0):.
  8. Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation
    Authors: G Del Monte-, M Ramialison, AAS Adam, B Wu, A Aharonov, G D'Uva, LM Bourke, ME Pitulescu, H Chen, JL de la Pomp, W Shou, RH Adams, SK Harten, E Tzahor, B Zhou, RP Harvey
    Nature, 2018;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: Bioassay
  9. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K?-selective Inhibitors in Breast Cancer
    Authors: YC Xu, X Wang, Y Chen, SM Chen, XY Yang, YM Sun, MY Geng, J Ding, LH Meng
    Theranostics, 2017;7(4):974-986.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV
    Authors: LC Schmitt, A Rau, O Seifert, J Honer, M Hutt, S Schmid, J Zantow, M Hust, S Dübel, MA Olayioye, RE Kontermann
    MAbs, 2017;0(0):0.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Ablation of neuropsin-neuregulin 1 signaling imbalances ErbB4 inhibitory networks and disrupts hippocampal gamma oscillation
    Authors: M Kawata, S Morikawa, S Shiosaka, H Tamura
    Transl Psychiatry, 2017;7(3):e1052.
    Applications: Bioassay
  12. The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis.
    Authors: McElroy S, Castle S, Bernard J, Almohazey D, Hunter C, Bell B, Al Alam D, Wang L, Ford H, Frey M
    Am J Pathol, 2014;184(10):2768-78.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  13. ErbB2 upregulates the Na+,HCO3(-)-cotransporter NBCn1/SLC4A7 in human breast cancer cells via Akt, ERK, Src, and Kruppel-like factor 4.
    Authors: Gorbatenko A, Olesen C, Morup N, Thiel G, Kallunki T, Valen E, Pedersen S
    FASEB J, 2014;28(1):350-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  14. Alveolar progenitor and stem cells in lung development, renewal and cancer.
    Authors: Desai, Tushar J, Brownfield, Douglas, Krasnow, Mark A
    Nature, 2014;507(7491):190-4.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Nuclear ErbB4 signaling through H3K9me3 is antagonized by EGFR-activated c-Src.
    Authors: Ishibashi K, Fukumoto Y, Hasegawa H, Abe K, Kubota S, Aoyama K, Kubota S, Nakayama Y, Yamaguchi N
    J Cell Sci, 2013;126(0):625-37.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  16. ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19.
    Authors: Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, Belzil V, Dion P, Higasa K, Doi K, Ishiura H, Mitsui J, Date H, Ahsan B, Matsukawa T, Ichikawa Y, Moritoyo T, Ikoma M, Hashimoto T, Kimura F, Murayama S, Onodera O, Nishizawa M, Yoshida M, Atsuta N, Sobue G, Fifita J, Williams K, Blair I, Nicholson G, Gonzalez-Perez P, Brown R, Nomoto M, Elenius K, Rouleau G, Fujiyama A, Morishita S, Goto J, Tsuji S
    Am J Hum Genet, 2013;93(5):900-5.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  17. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
    Authors: Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
    Nature, 2012;487(7408):505-9.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  18. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Authors: Hickinson DM, Klinowska T, Speake G
    Clin. Cancer Res., 2010;16(4):1159-69.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reconstitution Buffers

Reviews for Recombinant Human NRG1/HRG1 Protein, CF

There are currently no reviews for this product. Be the first to review Recombinant Human NRG1/HRG1 Protein, CF and earn rewards!

Have you used Recombinant Human NRG1/HRG1 Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review